What’s the main difference between Wegovy and Ozempic?
Wegovy and Ozempic are both injectable medicines that contain the same active ingredient: semaglutide. They differ mainly in the dosing schedule and the approved use.
- Ozempic is approved for type 2 diabetes and is prescribed to improve blood sugar control. [1]
- Wegovy is approved for chronic weight management to help with weight loss in people with obesity or overweight plus related conditions. [2]
How do their dosing and “strength” compare?
Both drugs use semaglutide, but the maximum dose and titration are different because the goals are different (diabetes control vs weight loss).
- Ozempic dosing is generally up to a lower maximum dose than Wegovy. [1]
- Wegovy is titrated up to higher semaglutide doses intended for weight loss. [2]
Are they taken the same way?
Yes. Both are once-weekly injections and work through the same general mechanism (mimicking a hormone called GLP-1 to reduce appetite and slow digestion). [1][2]
Which one is better for weight loss or diabetes?
They are not interchangeable in practice because each is approved for a different condition and typically uses different target doses.
- For weight loss, Wegovy is the product approved specifically for that purpose. [2]
- For blood sugar control in type 2 diabetes, Ozempic is the product approved for that purpose. [1]
What side effects are similar?
Because both contain semaglutide, they share common GLP-1-type side effects, especially gastrointestinal issues (like nausea, vomiting, diarrhea, constipation) and reduced appetite. [1][2]
Can switching between them make sense?
Clinicians may consider semaglutide products differently depending on whether the goal is diabetes management or weight loss, but the dosing differs. Any switch should be guided by a prescriber to match the right titration and target dose for the intended use. [1][2]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s018lbl.pdf